This article is more than 5 years old. Information may no longer be current.
Suneva Medical to license ReGenica globally
Click Here to Manage Email Alerts
Suneva Medical announced it has changed its international licensing agreement with Histogen to become the exclusive licensee for distributing the physician-dispensed ReGenica skincare line in Europe, most of Asia, South America, Canada, Australia and the Middle East.
Physician-dispensed ReGenica will continue to be exclusively licensed by Suneva Medical in the United States, according to a press release. Histogen’s proprietary Multipotent Cell Conditioned Media with growth factors and stem-cell derived proteins are contained in ReGenica products, the release said.
“[ReGenica’s] unique formula triggers cells to naturally produce proteins associated with skin renewal and healing,” Gail K. Naughton, PhD, chief executive officer and chairman of the board at Histogen, said in the release.
“With this amended licensing agreement in place, international consumers will now have access to the latest US growth-factor technology,” Nicholas L. Teti Jr., chairman and chief executive officer of Suneva Medical, said in the release.